

CLAIMS

1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a CD20 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein said CD20 binding domain comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), wherein the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprise:

- (i) SEQ ID NOs: 147, 148, 149, 136, 137, and 138, respectively;
- (ii) SEQ ID NOs: 150, 151, 152, 139, 140, and 141, respectively;
- (iii) SEQ ID NOs: 153, 154, 155, 142, 143, and 144, respectively; or
- (iv) SEQ ID NOs: 929, 930, 931, 926, 927, and 928, respectively.

2. The isolated nucleic acid molecule of claim 1, wherein the encoded CAR comprises a light chain variable region and a heavy chain variable region, wherein:

- (i) the light chain variable region comprises the amino acid sequence of SEQ ID NO: 156, 129, or 439;
- (ii) the light chain variable region comprises an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the light chain variable region of SEQ ID NO: 156, 129, or 439;
- (iii) the light chain variable region comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 156, 129, or 439;
- (iv) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 145, 118, or 437;
- (v) the heavy chain variable region comprises an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 145, 118, or 437;
- (vi) the heavy chain variable region comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 145, 118, or 437; or

(vii) the light chain variable region and the heavy chain variable region comprise:

- (a) SEQ ID NOs: 156 and 145, respectively;
- (b) SEQ ID NOs: 129 and 118 respectively; or
- (c) SEQ ID NOs: 439 and 437, respectively.

3. The isolated nucleic acid molecule of claim 1 or 2, wherein:

- (i) the CD20 binding domain is a scFv;
- (ii) the CD20 binding domain comprises the amino acid sequence of SEQ ID NO: 159 or SEQ ID NO: 132, or an amino acid sequence with at least 95% identity thereto, or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications relative to any of the aforesaid amino acid sequences; or
- (iii) the nucleic acid sequence encoding the CD20 binding domain comprises the nucleotide sequence of SEQ ID NO: 160 or SEQ ID NO: 133, or a nucleotide sequence with at least 95% identity thereto.

4. The isolated nucleic acid molecule of any of claims 1-3, wherein the nucleic acid molecule comprises:

- (i) the nucleotide sequence of SEQ ID NO: 146, SEQ ID NO: 119, SEQ ID NO: 438, SEQ ID NO: 157, SEQ ID NO: 130, SEQ ID NO: 440, or a nucleotide sequence with at least 95% identity thereto; or
- (ii) the nucleotide sequence of SEQ ID NOs: 157 and 146, SEQ ID NOs: 130 and 119, or SEQ ID NOs: 440 and 438.

5. The isolated nucleic acid molecule of any one of claims 1-4, wherein:

- (i) the transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD123, CD134, CD137 and CD154;
- (ii) the transmembrane domain comprises an amino acid sequence comprising at least one, two or three modifications but not more than 5 modifications of the amino acid sequence of

SEQ ID NO: 801, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 801;

(iii) the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 801;

(iv) the nucleic acid sequence encoding the transmembrane domain comprises the nucleotide sequence of SEQ ID NO: 802, or a nucleotide sequence with at least 99% identity thereto;

(v) the CD20 binding domain is connected to the transmembrane domain by a hinge region;

(vi) the CD20 binding domain is connected to the transmembrane domain by a hinge region, wherein the hinge region comprises the amino acid sequence of SEQ ID NO: 799, or SEQ ID NO: 814, or an amino acid sequence with at least 99% identity thereto; or

(vii) the CD20 binding domain is connected to the transmembrane domain by a hinge region, wherein the nucleic acid sequence encoding the hinge region comprises the nucleotide sequence of SEQ ID NO: 800 or SEQ ID NO: 815, or a nucleotide sequence with at least 99% identity thereto.

6. The isolated nucleic acid molecule of any one of claims 1-5, wherein:

(i) the intracellular signaling domain comprises a costimulatory domain;

(ii) the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain is a functional signaling domain obtained from a protein selected from the group consisting of OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278) and 4-1BB (CD137);

(iii) the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 5 modifications of the amino acid sequence of SEQ ID NO: 803, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 803;

(iv) the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 803;

(v) the intracellular signaling domain comprises a costimulatory domain, wherein the nucleic acid sequence encoding the costimulatory domain comprises the nucleotide sequence of SEQ ID NO: 804, or a nucleotide sequence with at least 99% identity thereto;

(vi) the intracellular signaling domain comprises a primary signaling domain;

(vii) the intracellular signaling domain comprises a primary signaling domain, wherein the primary signaling domain comprises a functional signaling domain of CD3 zeta;

(viii) the intracellular signaling domain comprises a primary signaling domain, wherein the primary signaling domain comprises the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807;

(ix) the intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;

(x) the intracellular signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than five modifications of the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807;

(xi) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807;

(xii) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 803 and the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807;

(xiii) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 803 and the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain; or

(xiv) the nucleic acid sequence encoding the intracellular signaling domain comprises the nucleotide sequence of SEQ ID NO: 804, or a nucleotide sequence with at least 99% identity thereto, and/or the nucleotide sequence of SEQ ID NO: 893, 808, 806, or 1074, or a nucleotide sequence with at least 99% identity thereto.

7. The isolated nucleic acid molecule of any one of claims 1-6, further comprising a leader sequence.

8. The isolated nucleic acid of claim 7, wherein the leader sequence encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 797.

9. The isolated nucleic acid molecule of any one of claims 1-8, wherein:

(i) the encoded CAR comprises the amino acid sequence of SEQ ID NO: 161 or SEQ ID NO: 134, or an amino acid sequence with at least 99% identity thereto, or an amino acid sequence comprising at least one, two or three modifications but not more than 5 modifications of the amino acid sequence of SEQ ID NO: 161 or SEQ ID NO: 134, wherein the CAR comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797;

(ii) the encoded CAR comprises the amino acid sequence of SEQ ID NO: 161 or SEQ ID NO: 134, wherein the CAR comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797;

(iii) the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 162 or SEQ ID NO: 135, or a nucleotide sequence with at least 99% identity thereto, wherein the nucleic acid molecule comprises or does not comprise the nucleotide sequence of SEQ ID NO: 798; or

(iv) the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 162 or SEQ ID NO: 135, wherein the nucleic acid molecule comprises or does not comprise the nucleotide sequence of SEQ ID NO: 798.

10. An isolated polypeptide molecule encoded by the nucleic acid molecule of any one of claims 1-9.

11. An isolated CAR molecule comprising a CD20 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD20 binding domain comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining

region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), wherein the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprise:

- (i) SEQ ID NOs: 147, 148, 149, 136, 137, and 138, respectively;
- (ii) SEQ ID NOs: 150, 151, 152, 139, 140, and 141, respectively;
- (iii) SEQ ID NOs: 153, 154, 155, 142, 143, and 144, respectively; or
- (iv) SEQ ID NOs: 929, 930, 931, 926, 927, and 928, respectively.

12. The isolated CAR molecule of claim 11, wherein the CAR molecule comprises a light chain variable region and a heavy chain variable region, wherein:

- (i) the light chain variable region comprises the amino acid sequence of SEQ ID NO: 156, 129, or 439;
- (ii) the light chain variable region comprises an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the light chain variable region of SEQ ID NO: 156, 129, or 439;
- (iii) the light chain variable region comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 156, 129, or 439;
- (iv) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 145, 118, or 437;
- (v) the heavy chain variable region comprises an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 145, 118, or 437;
- (vi) the heavy chain variable region comprises an amino acid sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 145, 118, or 437; or
- (vii) the light chain variable region and the heavy chain variable region comprise:
 - (a) SEQ ID NOs: 156 and 145, respectively;
 - (b) SEQ ID NOs: 129 and 118 respectively; or
 - (c) SEQ ID NOs: 439 and 437, respectively.

13. The isolated CAR molecule of claim 11 or 12, wherein:

- (i) the CD20 binding domain is an scFv; or

(ii) the CD20 binding domain comprises the amino acid sequence of SEQ ID NO: 159 or SEQ ID NO: 132, or an amino acid sequence with at least 95% identity thereto.

14. The isolated CAR molecule of any one of claims 11-13, wherein:

(i) the CAR molecule comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD123, CD134, CD137 and CD154;

(ii) the transmembrane domain comprises an amino acid sequence having at least one, two or three modifications but not more than 5 modifications of the amino acid sequence of SEQ ID NO: 801, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 801;

(iii) the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 801;

(iv) the CD20 binding domain is connected to the transmembrane domain by a hinge region, wherein the hinge region comprises the amino acid sequence of SEQ ID NO: 799, or SEQ ID NO: 814, or an amino acid sequence with at least 99% identity thereto.

15. The isolated CAR molecule of any one of claims 11-14, wherein:

(i) the intracellular signaling domain comprises a costimulatory domain;

(ii) the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises a functional signaling domain of a protein selected from the group consisting of OX40, CD2, CD27, CD28, CD29, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278) and 4-1BB (CD137);

(iii) the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 5 modifications of the amino acid sequence of SEQ ID NO: 803, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 803;

(iv) the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 803;

(v) the intracellular signaling domain comprises a primary signaling domain;

(vi) the intracellular signaling domain comprises a primary signaling domain, wherein the primary signaling domain comprises a functional signaling domain of CD3 zeta;

(vii) the intracellular signaling domain comprises a primary signaling domain, wherein the primary signaling domain comprises the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807;

(viii) the intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;

(ix) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 805;

(x) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 807;

(xi) the intracellular signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than 5 modifications of the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 803 and/or the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807; or

(xii) the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 803 and the amino acid sequence of SEQ ID NO: 805 or SEQ ID NO: 807, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

16. The isolated CAR molecule of any one of claims 11-15, further comprising a leader sequence.

17. The isolated CAR molecule of claim 16, wherein the leader sequence comprises the amino acid sequence of SEQ ID NO: 797, or an amino acid sequence with at least 99% identity to the amino acid sequence of SEQ ID NO: 797.

18. The isolated CAR molecule of any one of claims 11-17, comprising:

(i) the amino acid sequence of SEQ ID NO: 161 or SEQ ID NO: 134, , or an amino acid sequence with at least 99% identity thereto or an amino acid sequence comprising at least one,

two or three modifications but not more than 5 modifications of the amino acid sequence of SEQ ID NO: 161 or SEQ ID NO: 134, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797; or

(ii) the amino acid sequence of SEQ ID NO: 161 or SEQ ID NO: 134, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

19. A CD20 binding domain comprising a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2), light chain complementarity determining region 3 (LCDR3), heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), wherein the LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, and HCDR3 comprise:

- (i) SEQ ID NOs: 147, 148, 149, 136, 137, and 138, respectively;
- (ii) SEQ ID NOs: 150, 151, 152, 139, 140, and 141, respectively;
- (iii) SEQ ID NOs: 153, 154, 155, 142, 143, and 144, respectively; or
- (iv) SEQ ID NOs: 929, 930, 931, 926, 927, and 928, respectively.

20. The CD20 binding domain of claim 19, wherein:

(i) the CD20 binding domain is a scFv;

(ii) the CD20 binding domain comprises a light chain variable region and a heavy chain variable region, wherein the amino acid sequence of the light chain variable region and the heavy chain variable region, comprise:

- (a) SEQ ID NOs: 156 and 145;
- (b) SEQ ID NOs: 129 and 118; or
- (c) SEQ ID NOs: 439 and 437;

(iii) the CD20 binding domain comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the amino acid sequence of SEQ ID NO: 156, SEQ ID NO: 129, or SEQ ID NO: 439, or an amino acid sequence with at least 95% identity to an amino acid sequence of

SEQ ID NO: 156, SEQ ID NO: 129, or SEQ ID NO: 439; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the amino acid sequence of

SEQ ID NO: 145, SEQ ID NO: 118, or SEQ ID NO: 437, or an amino acid sequence with at least 95% identity to an amino acid sequence of SEQ ID NO: 145, SEQ ID NO: 118, or SEQ ID NO: 437; or

(iv) the CD20 binding domain comprises the amino acid sequence of SEQ ID NO: 159 or SEQ ID NO: 132, or an amino acid sequence with at least 95% identity thereto.

21. A nucleic acid molecule comprising:

(i) a first nucleic acid molecule encoding the CAR molecule of any one of claims 10-16, and

(ii) a second nucleic acid molecule encoding a CAR molecule that binds a B-cell antigen.

22. The nucleic acid of claim 21, wherein the first and the second nucleic acid molecules are disposed on a single nucleic acid molecule or the first and the second nucleic acid molecules are disposed on separate nucleic acid molecules.

23. The nucleic acid molecule of claim 21 or 22, wherein the B-cell antigen is:

(i) CD19, CD22, CD10, CD34, CD123, FLT-3, ROR-1, CD79b, CD79a, or CD179b; or

(ii) CD19 or CD22.

24. The nucleic acid molecule of any one of claims 21-23, wherein the CAR molecule that binds to a B-cell antigen binds to CD19 and comprises:

(i) a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising SEQ ID NOs: 773, 774, 775, 776, 777, and 778, respectively

(ii) a scFv comprising the amino acid sequence of SEQ ID NO: 765; or

(iii) a CAR comprising the amino acid sequence of SEQ ID NO: 764, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

25. The nucleic acid molecule of any one of claims 21-23, wherein the CAR molecule that binds to a B-cell antigen binds to CD19 and comprises:

(i) a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising SEQ ID NOs: 785, 786, 787, 788, 789, and 790, respectively;

(ii) a scFv comprising the amino acid sequence of SEQ ID NO: 1047; or

(iii) a CAR comprising the amino acid sequence of SEQ ID NO: 1049, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

26. The isolated nucleic acid molecule of any one of claims 21-23, wherein the CAR molecule that binds to a B-cell antigen binds to CD22 and comprises:

(i) a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising:

(a) SEQ ID NOs: 719, 720, 721, 730, 731, and 732, respectively;

(b) SEQ ID NOs: 722, 723, 724, 733, 734, and 735, respectively;

(c) SEQ ID NOs: 725, 726, 727, 736, 737, and 738, respectively; or

(d) SEQ ID NOs: 1036, 1037, 1038, 1039, 1040, and 1041, respectively;

(ii) a scFv comprising the amino acid sequence of SEQ ID NO: 742, 835, 836, or 837; or

(iii) a CAR comprising the amino acid sequence of SEQ ID NO: 744, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

27. The nucleic acid molecule of any one of claims 21-26, wherein:

(i) a nucleotide sequence encoding a cleavable peptide, or a nucleotide sequence encoding an IRES is disposed between the first nucleic acid molecule and the second nucleic acid molecule;

(ii) the first nucleic acid molecule and the second nucleic acid molecule comprise a single promoter;

(iii) the first nucleic acid molecule and the second nucleic acid molecule comprise a single promoter, wherein the single promoter is an EF-1 α promoter;

(iv) the first nucleic acid molecule comprises a first promoter and the second nucleic acid molecule comprises a second promoter; or

(v) the nucleic acid molecule comprises RNA or DNA.

28. The nucleic acid molecule of claim 27, wherein:

(i) the cleavable peptide is a P2A or F2A;

(ii) the first nucleic acid molecule and the second nucleic acid molecule comprise a single promoter as a bicistronic transcription product; and/or

(iii) the EF-1 α promoter comprises the nucleotide sequence of SEQ ID NO: 833.

29. An isolated polypeptide molecule encoded by the nucleic acid molecule of any one of claims 21-28.

30. A multispecific antibody molecule, or CAR molecule, having a first binding specificity for CD20 and a second binding specificity for one or more of CD19, CD22, CD10, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a, wherein the first binding specificity comprises the CD20 binding domain of claim 19 or 20.

31. A nucleic acid molecule encoding the multispecific antibody molecule or the CAR molecule of claim 30.

32. A vector, comprising the nucleic acid molecule of any one of claims 1-9, 21-28 or 31, a nucleic acid molecule encoding the isolated polypeptide molecule of claim 10 or 29, a nucleic acid molecule encoding the isolated CAR molecule of any one of claims 11-18, a nucleic acid molecule encoding the CD20 binding domain of claim 19 or 20, or a nucleic acid molecule encoding the multispecific antibody molecule or CAR molecule of claim 30.

33. The vector of claim 32, wherein the vector is selected from the group consisting of a DNA, a RNA, a plasmid, a lentivirus vector, an adenoviral vector, or a retrovirus vector.

34. A population of immune effector cells, comprising the nucleic acid molecule of any one of claims 1-9, 21-28, or 31, the isolated polypeptide molecule of claim 10 or 29, the isolated CAR molecule of any one of claims 11-18, the CD20 binding domain of claim 19 or 20, the multispecific antibody molecule of claim 30, or the vector of claim 32 or 33, wherein the population of immune effector cells comprises T cells or NK cells.

35. An *ex vivo* method of making a population of immune effector cells, comprising transducing a T cell or an NK cell with the nucleic acid molecule of any one of claims 1-9, 21-28, or 31 or the vector of claim 32 or 33.

36. An *in vitro* or *ex vivo* method of generating a population of RNA-engineered cells comprising introducing an *in vitro* transcribed RNA or synthetic RNA into a cell, wherein the RNA comprises the nucleic acid molecule of any one of claims 1-9, 21-28, or 31, wherein the population of RNA-engineered cells comprises T cells or NK cells.

37. A population of immune effector cells, comprising:

(i) a first cell population comprising the nucleic acid molecule of any one of claims 1-9, 21-28, or 31, the isolated polypeptide molecule of claim 10 or 29, the isolated CAR molecule of any one of claims 11-18, the CD20 binding domain of claim 19 or 20, or the vector of claim 32 or 33;

and

(ii) a second cell population comprising a nucleic acid molecule encoding a CAR that binds a B-cell antigen,

wherein the population of immune effector cells comprises T cells or NK cells.

38. The population of immune effector cells of claim 37, wherein the B-cell antigen is:

(i) CD19, CD22, CD10, CD34, CD123, FLT-3, ROR-1, CD79b, CD79a, or CD179; or

(ii) CD19 or CD22.

39. The population of immune effector cells of claim 37 or 38, wherein the CAR that binds a B-cell antigen binds CD19 and comprises a nucleotide sequence encoding a CD19 CAR wherein the CD19 CAR comprises:

(i) a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising SEQ ID NOs: 773, 774, 775, 776, 777, and 778, respectively

(ii) a scFv comprising the amino acid sequence of SEQ ID NO: 765; or

(iii) a CAR comprising the amino acid sequence of SEQ ID NO: 764, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

40. The population of immune effector cells of claim 37 or 38, wherein the CAR that binds a B-cell antigen binds CD19 and comprises a nucleotide sequence encoding a CD19 CAR, wherein the CD19 CAR comprises:

(i) a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising SEQ ID NOs: 785, 786, 787, 788, 789, and 790, respectively;

(ii) a scFv comprising the amino acid sequence of SEQ ID NO: 1047; or

(iii) a CAR comprising the amino acid sequence of SEQ ID NO: 1049, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

41. The population of immune effector cells of claim 37 or 38, wherein the CAR that binds a B-cell antigen binds CD22 and comprises a nucleotide sequence encoding a CD22 CAR wherein the CD22 CAR comprises:

(i) a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising:

(a) SEQ ID NOs: 719, 720, 721, 730, 731, and 732, respectively;

(b) SEQ ID NOs: 722, 723, 724, 733, 734, and 735, respectively;

(c) SEQ ID NOs: 725, 726, 727, 736, 737, and 738, respectively; or

(d) SEQ ID NOs: 1036, 1037, 1038, 1039, 1040, and 1041, respectively;

(ii) a scFv comprising the amino acid sequence of SEQ ID NO: 742, 835, 836, or 837; or

(iii) a CAR comprising the amino acid sequence of SEQ ID NO: 744, wherein the CAR molecule comprises or does not comprise a signal peptide comprising the amino acid sequence of SEQ ID NO: 797.

42. Use of a population of immune effector cells, expressing the nucleic acid molecule of any one of claims 1-9, 21-28, or 31, the isolated polypeptide molecule of claim 10 or 29, the isolated CAR molecule of any one of claims 11-18, the CD20 binding domain of claim 19 or 20, the multispecific antibody molecule of claim 30, or the vector of claim 32 or 33, in the manufacture of a medicament for the treatment of a cancer
, wherein said use comprises an effective amount of the cell to be administered to the subject, wherein the population of immune effector cells comprises T cells or NK cells.

43. The use of claim 42, wherein:

(i) the cancer is acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (BALL), small lymphocytic lymphoma (SLL), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, hairy cell leukemia, small cell-lymphoma, large cell-follicular lymphoma, a malignant lymphoproliferative condition, MALT lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia, or myelodysplastic syndrome, myeloproliferative neoplasm, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, preleukemia, or a combination thereof;

(ii) the cancer is lymphoma;

(iii) the cancer is a diffuse large B cell lymphoma (DLBCL); or

(iv) the cancer is a B-cell malignancy.

44. The use of claim 42 or 43, further comprising a B-cell inhibitor to be administered to the subject, wherein the B-cell inhibitor is chosen from one or more of an inhibitor of CD19, CD22, CD10, CD34, CD123, FLT-3, ROR-1, CD79b, CD79a, or CD179b.

45. The use of claim 44, wherein:

- (i) the B-cell inhibitor is a small molecule inhibitor;
- (ii) the B-cell inhibitor is a polypeptide, a soluble ligand, an antibody, or an antigen-binding fragment thereof that binds to one or more of CD10, CD19, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a;
- (iii) the B-cell inhibitor is an inhibitory nucleic acid, wherein the inhibitor nucleic acid comprises a dsRNA, a siRNA, or an shRNA;
- (iv) the B-cell inhibitor is a population of immune effector cells, expressing a CAR that binds a B-cell antigen, wherein the B-cell antigen comprises CD19, CD22, CD10, CD34, CD123, FLT-3, ROR-1, CD79b, CD79a, or CD179b;
- (v) the B-cell inhibitor is to be administered prior to the population of immune effector cells expressing a CAR molecule;
- (vi) the B-cell inhibitor is to be administered concurrently with the population of immune effector cells, expressing a CAR molecule; or
- (vii) the B-cell inhibitor is to be administered after the population of immune effector cells, expressing a CAR molecule.

46. The use of any one of claims 42-45, wherein the population of immune effector cells is to be administered in combination with: (i) an agent that ameliorates one or more side effects associated with administration of the cell; or

- (ii) an agent that treats the cancer.

47. The population of immune effector cells of any one of claims 37-41, further expressing an inhibitory molecule comprises a first polypeptide that comprises at least a portion of Programmed Death 1 (PD1) and a second polypeptide comprising a costimulatory domain and primary signaling domain.

48. Use of an inhibitor of CD20 in the manufacture of a medicament for treating a patient who has a cancer and is a non-responder, partial responder, or relapser to a CD19 inhibitor, wherein the inhibitor of CD20 is encoded by the nucleic acid molecule of any one of claims 1-9, 21-28, or 31.

49. Use of claim 48, wherein the CD19 inhibitor comprises a CD19 CAR therapy.